Should biologics for psoriasis be interrupted in the era of COVID-19?
Author:
Funder
AbbVie
Amgen
Eli Lilly
Janssen Research and Development, LLC
Novartis
Ortho Dermatologics
UCB
Publisher
Elsevier BV
Subject
Dermatology
Reference4 articles.
1. The IL-12 family of cytokines in infection, inflammation and autoimmune disorders;Gee;Inflamm Allergy Drug Targets,2009
2. Successful treatment of moderate to severe plaque psoriasis with the PEGylated Fab' certolizumab pegol: results of a phase II randomized, placebo-controlled trial with a re-treatment extension;Reich;Br J Dermatol,2012
3. Patients with moderate-to-severe psoriasis recapture clinical response during re-treatment with etanercept;Ortonne;Br J Dermatol,2009
4. Continuous dosing versus interrupted therapy with ixekizumab: an integrated analysis of two phase 3 trials in psoriasis [published correction appears in J Eur Acad Dermatol Venereol. 2017;31(10):1764];Blauvelt;J Eur Acad Dermatol Venereol,2017
Cited by 137 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Vaccination Rates in Patients with Chronic Inflammatory Skin Diseases and Immunomodulatory Systemic Therapies—Vaccinations against SARS-CoV-2, Influenza Virus or Varicella Zoster Virus;Life;2024-09-12
2. Identification of angiogenesis-related genes and molecular subtypes for psoriasis based on random forest algorithm;Clinical and Experimental Immunology;2024-06-28
3. Basic Susceptibility of Patients with Psoriasis under Systemic Therapy for Respiratory Infections: Data from the German Psoriasis Registry PsoBest;Journal of Clinical Medicine;2024-06-26
4. Perception and Impact of COVID-19 Pandemic in Psoriasis Patients: Data from the German PsoBest and the CoronaBest Registries;Psoriasis: Targets and Therapy;2024-05
5. A call for guidance on the treatment of patients taking disease-modifying anti-rheumatic drugs (DMARDs);British Journal of Oral and Maxillofacial Surgery;2024-05
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3